Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits

Public funding is backing a new immunotherapy treatment, but the bulk of any profits will go to a private company. So are taxpayers getting a good deal?
By MATT RICHTEL and ANDREW POLLACK from NYT Health http://ift.tt/2hjPPDW
via IFTTT
Drugs (Pharmaceuticals)
Source The New York Times
Làm đẹp Blog 247